Early Onset Androgenetic Alopecia in Men and Associated Risk Factors: A Hospital-Based Study

    May 2017 in “ International Journal of Research in Dermatology ”
    Thansiha Nargis, Vishal Bejai, Malcolm Pinto, Manjunath Mala Shenoy
    TLDR Early onset hair loss in young men is common and linked to family history and alcohol use.
    The study investigated early onset androgenetic alopecia (AGA) in men and its associated risk factors, involving 103 male patients over 18 years old. It found that 68% of participants were aged 21-30, and a significant association was observed between early AGA onset and alcohol consumption (73.3%). Familial AGA was prevalent in 68% of cases, with paternal inheritance (62.8%) being more common than maternal (8.6%). Systemic diseases were present in 12.6% of patients, with hypertension being the most common. The study concluded that early onset AGA is common in younger men, often causing anxiety, and emphasized the importance of early management, especially in those with a family history. Environmental factors like smoking and alcohol were considered potential contributors to AGA.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 1 year ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community DLQ01: A Better "Minoxidil" PGF2a synthetic analogue.

      in Research/Science  3 upvotes 9 months ago
      DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

      community Am I missing something with pp405?

      in Research/Science  32 upvotes 10 months ago
      PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

      community Quote from Pelage (PP-405) Spokesperson...

      in Research/Science  121 upvotes 1 month ago
      Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

      community Androgenetic alopecia is a skin disease: DHT-mediated skin disorders

      in Research/Science  63 upvotes 2 years ago
      Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

    Related Research

    14 / 14 results